{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:25:41Z","timestamp":1776399941929,"version":"3.51.2"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jphs.2021.01.005","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T11:46:47Z","timestamp":1611143207000},"page":"289-295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Gastrodin - A potential drug used for the treatment of Tourette Syndrome"],"prefix":"10.1016","volume":"145","author":[{"given":"Yuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An-Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jphs.2021.01.005_bib1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1875-9572(10)60050-2","article-title":"Tourette syndrome in children: an updated review","volume":"51","author":"Du","year":"2010","journal-title":"Pediatr Neonatol"},{"issue":"5","key":"10.1016\/j.jphs.2021.01.005_bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jpsychores.2008.03.006","article-title":"The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 1: the epidemiological and prevalence studies","volume":"65","author":"Robertson","year":"2008","journal-title":"J\u00a0Psychosom Res"},{"issue":"2","key":"10.1016\/j.jphs.2021.01.005_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pediatrneurol.2012.05.002","article-title":"Prevalence of tic disorders: a systematic review and meta-analysis","volume":"47","author":"Knight","year":"2012","journal-title":"Pediatr Neurol"},{"issue":"1 Pt 1","key":"10.1016\/j.jphs.2021.01.005_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1542\/peds.102.1.14","article-title":"Course of tic severity in Tourette syndrome: the first two decades","volume":"102","author":"Leckman","year":"1998","journal-title":"Pediatrics"},{"issue":"9345","key":"10.1016\/j.jphs.2021.01.005_bib5","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)11526-1","article-title":"Tourette's syndrome","volume":"360","author":"Leckman","year":"2002","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jphs.2021.01.005_bib6","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1212\/WNL.0b013e3182104106","article-title":"Abnormal metabolic brain networks in Tourette syndrome","volume":"76","author":"Pourfar","year":"2011","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jphs.2021.01.005_bib7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/chi.0b013e318068fbcc","article-title":"Tourette syndrome and tic disorders: a decade of progress","volume":"46","author":"Swain","year":"2007","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"10.1016\/j.jphs.2021.01.005_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0925-4927(94)90014-0","article-title":"Dopamine receptor availability in Tourette's syndrome","volume":"55","author":"George","year":"1994","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.jphs.2021.01.005_bib9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/ana.21809","article-title":"Extrastriatal dopaminergic dysfunction in tourette syndrome","volume":"67","author":"Steeves","year":"2010","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.jphs.2021.01.005_bib10","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.neubiorev.2012.10.004","article-title":"Neuromodulation in Tourette syndrome: dopamine and beyond","volume":"37","author":"Buse","year":"2013","journal-title":"Neurosci Biobehav Rev"},{"issue":"6","key":"10.1016\/j.jphs.2021.01.005_bib11","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/sj.npp.1301528","article-title":"Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in\u00a0vivo neurochemistry study with PET","volume":"33","author":"Wong","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"1 Suppl","key":"10.1016\/j.jphs.2021.01.005_bib12","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1007\/BF02245006","article-title":"Interaction of antipsychotic drugs with neurotransmitter receptor sites in\u00a0vitro and in\u00a0vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors","volume":"112","author":"Leysen","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"10.1016\/j.jphs.2021.01.005_bib13","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archpsyc.1989.01810080052006","article-title":"Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome","volume":"46","author":"Shapiro","year":"1989","journal-title":"Arch Gen Psychiatr"},{"issue":"1","key":"10.1016\/j.jphs.2021.01.005_bib14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/0269881104040251","article-title":"Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity","volume":"18","author":"Bressan","year":"2004","journal-title":"J\u00a0Psychopharmacol"},{"issue":"1","key":"10.1016\/j.jphs.2021.01.005_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s13311-013-0215-4","article-title":"Treatment of tourette syndrome","volume":"11","author":"Kurlan","year":"2014","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.jphs.2021.01.005_bib16","first-page":"169","article-title":"Traditional Chinese medicine Ningdong granule: the beneficial effects in Tourette's disorder","volume":"38","author":"Zhao","year":"2010","journal-title":"J\u00a0Int Med Res"},{"issue":"4","key":"10.1016\/j.jphs.2021.01.005_bib17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00213-011-2238-z","article-title":"Ningdong granule: a complementary and alternative therapy in the treatment of attention deficit\/hyperactivity disorder","volume":"216","author":"Li","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"10.1016\/j.jphs.2021.01.005_bib18","first-page":"399","article-title":"[Studies on some pharmacological effects of gastrodia injection and gastrodin]","volume":"7","author":"Huang","year":"1985","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"10.1016\/j.jphs.2021.01.005_bib19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fphar.2018.00024","article-title":"A\u00a0review on central nervous system effects of gastrodin","volume":"9","author":"Liu","year":"2018","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jphs.2021.01.005_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0149-7634(89)80050-8","article-title":"The iminodipropionitrile (IDPN)-induced dyskinetic syndrome: behavioral and biochemical pharmacology","volume":"13","author":"Cadet","year":"1989","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"10.1016\/j.jphs.2021.01.005_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pjnns.2017.10.015","article-title":"Aripiprazole in treatment of Gilles de la Tourette syndrome - new therapeutic option","volume":"52","author":"Janik","year":"2018","journal-title":"Neurol Neurochir Pol"},{"issue":"2","key":"10.1016\/j.jphs.2021.01.005_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/WCO.0b013e328344648c","article-title":"Recent advances in Tourette syndrome","volume":"24","author":"Bloch","year":"2011","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"10.1016\/j.jphs.2021.01.005_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1358\/dot.2014.50.2.2097801","article-title":"Current pharmacotherapeutic approaches for the treatment of Tourette syndrome","volume":"50","author":"Egolf","year":"2014","journal-title":"Drugs Today (Barc)"},{"issue":"1","key":"10.1016\/j.jphs.2021.01.005_bib24","first-page":"79","article-title":"Serum haloperidol levels in Gilles de la Tourette syndrome","volume":"16","author":"Singer","year":"1981","journal-title":"Biol Psychiatr"},{"issue":"2\u20133","key":"10.1016\/j.jphs.2021.01.005_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0165-0173(97)00063-5","article-title":"Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain research","volume":"26","author":"Gainetdinov","year":"1998","journal-title":"Brain Res Rev"},{"issue":"7","key":"10.1016\/j.jphs.2021.01.005_bib26","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/sj.npp.1300963","article-title":"The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation","volume":"31","author":"Lodge","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.jphs.2021.01.005_bib27","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","article-title":"A\u00a0double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder","volume":"57","author":"McDougle","year":"2000","journal-title":"Arch Gen Psychiatr"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861321000062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861321000062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:00:55Z","timestamp":1761163255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861321000062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1347861321000062"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2021.01.005","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastrodin - A potential drug used for the treatment of Tourette Syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2021.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}